The US Food and Drug Administration released drug safety communications and labeling updates on Friday, closing out its July regulatory review cycle with new warnings and prescribing changes for several marketed medicines. The agency posted the notices through its MedWatch safety alert system.

The communications form part of the FDA's routine end-of-month publication of adverse event assessments drawn from its FAERS reporting database. The agency's Center for Drug Evaluation and Research regularly issues such updates when accumulated post-marketing data warrant revised labeling, boxed warnings or restricted use.

Among the areas under recent scrutiny have been GLP-1 receptor agonists such as semaglutide, which continue to draw regulatory attention as manufacturers including Sun Pharma expand into new markets. The FDA has repeatedly flagged supply, compounding and off-label safety concerns tied to the fast-growing class.

Patient safety advocates and pharmacists welcomed the transparency but urged clearer communication with prescribers. The American Society of Health-System Pharmacists has previously called on the FDA to distribute labeling changes more directly to clinicians rather than relying solely on website postings.

The FDA said it would continue to monitor real-world data and issue further guidance as needed, and it encouraged health professionals and consumers to report suspected adverse events through the MedWatch portal.